18 F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18 F-Florbetapir in Alzheimer’s Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis
Restricted accessResearch articleFirst published online August 20, 2019
18 F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18 F-Florbetapir in Alzheimer’s Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis
18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) and 18F-florbetapir PET are approved neuroimaging biomarkers for the Alzheimer’s disease (AD) and mild cognitive impairment (MCI).
Objectives:
This study aims to compare the efficacy of 18F-FDG and 18F-florbetapir PET at evaluating the cognitive performance of patients with AD, MCI, and normal controls (NC).
Methods:
63 subjects (36 male/27 female, mean age = 68.3) including 19 AD, 23 MCI, and 21 NC underwent 18F-FDG and 18F-florbetapir PET imaging. A global quantification approach was applied on supra-tentorial, frontal, parieto-occipital, temporal, and cerebellar brain regions by calculating the global SUVmean ratios (GSUVr) as the weighted average of all regional SUVmean. 18F-FDG and 18F-florbetapir GSUVr of each region were subsequently correlated with the Mini-Mental State Examination (MMSE).
Results:
Subjects were studied in five categories as NC, MCI patients, AD patients, MCI and AD patients grouped together (MCI/AD), and a group including all the subjects (NC/MCI/AD). Both 18F-FDG and 18F-florbetapir could successfully detect subjects with dementia (p < 0.001). Studied in all regions and groups, the correlation analysis of 18F-FDG GSUVr with MMSE scores was significant in more regions and groups compared to that of 18F-florbetapir. We also demonstrated that the correlation of 18F-FDG GSUVr with MMSE is stronger than that of 18F-florbetapir in the supra-tentorial and temporal regions.
Conclusions:
This study reveals how 18F-FDG-PET global quantification is a superior indicator of cognitive performance in AD and MCI patients compared to 18F-florbetapir PET. Accordingly, we still recommend 18F-FDG-PET over amyloid imaging in the evaluation for AD and MCI.
TaylorCA, GreenlundSF, McGuireLC, LuH, CroftJB (2017) Deaths from Alzheimer’s Disease - United States, 1999-2014. MMWR Morb Mortal Wkly Rep66, 521–526.
2.
Alzheimer’s Association (2017) 2017 Alzheimer’s disease facts and figures. Alzheimers Dement13, 325–373.
3.
BarkerWW, LuisCA, KashubaA, LuisM, HarwoodDG, LoewensteinD, WatersC, JimisonP, ShepherdE, SevushS, Graff-RadfordN, NewlandD, ToddM, MillerB, GoldM, HeilmanK, DotyL, GoodmanI, RobinsonB, PearlG, DicksonD, DuaraR (2002) Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord16, 203–212.
4.
WilsonRS, SegawaE, BoylePA, AnagnosSE, HizelLP, BennettDA (2012) The natural history of cognitive decline in Alzheimer’s disease. Psychol Aging27, 1008–1017.
5.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–944.
6.
PetersenRC, CaraccioloB, BrayneC, GauthierS, JelicV, FratiglioniL (2014) Mild cognitive impairment: A concept in evolution. J Intern Med275, 214–228.
7.
AlbertMS, DekoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
8.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCR, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
9.
KnopmanDS, DeKoskyST, CummingsJL, ChuiH, Corey-BloomJ, RelkinN, SmallGW, MillerB, StevensJC (2001) Practice parameter: Diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology56, 1143–1153.
10.
HymanBT, PhelpsCH, BeachTG, BigioEH, CairnsNJ, CarrilloMC, DicksonDW, DuyckaertsC, FroschMP, MasliahE, MirraSS, NelsonPT, SchneiderJA, ThalDR, ThiesB, TrojanowskiJQ, VintersH V, MontineTJ (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement8, 1–13.
11.
SilvermanDHS, SmallGW, ChangCY, LuCS, de Aburto MAK, ChenW, CzerninJ, RapoportSI, PietriniP, AlexanderGE, SchapiroMB, JagustWJ, HoffmanJM, Welsh-BohmerKA, AlaviA, ClarkCM, SalmonE, de Leon MJ, MielkeR, CummingsJL, KowellAP, GambhirSS, HohCK, PhelpsME (2001) Positron emission tomography in evaluation of dementia. JAMA286, 2120.
MosconiL, TsuiWH, HerholzK, PupiA, DrzezgaA, LucignaniG, ReimanEM, HolthoffV, KalbeE, SorbiS, Diehl-SchmidJ, PerneczkyR, ClericiF, CaselliR, Beuthien-BaumannB, KurzA, MinoshimaS, de Leon MJ (2008) Multicenter dtandardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. J Nucl Med49, 390–398.
14.
MosconiL (2005) Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease: FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging32, 486–510.
15.
HymanBT (2011) Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch Neurol68, 1062–1064.
16.
DrzezgaA, GrimmerT, RiemenschneiderM, LautenschlagerN, SiebnerH, AlexopoulusP, MinoshimaS, SchwaigerM, KurzA (2005) Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med46, 1625–1632.
17.
DupontA, Santiago RibeiroM, GuilloteauD, ArlicotN (2017) β-amyloid PET neuroimaging: A review of radiopharmaceutical development. Méd Nucl41, 27–35.
18.
WolkDA, ZhangZ, BoudharS, ClarkCM, PontecorvoMJ, ArnoldSE (2012) Amyloid imaging in Alzheimer’s disease: Comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry83, 923–926
.
19.
LandauSM, BreaultC, JoshiAD, PontecorvoM, MathisCA, JagustWJ, MintunMA (2013) Amyloid-imaging with Pittsburgh Compound B and Florbetapir: Comparing radiotracers and quantification methods. J Nucl Med54, 70–77.
20.
RiceL, BisdasS (2017) The diagnostic value of FDG and amyloid PET in Alzheimer’s disease—A systematic review. Eur J Radiol94, 16–24.
21.
MintunM, JoshiA, PontecorvoM, LuM, KrautkramerM, CarpenterA, BedellB, FleisherA, SkovronskyD, BeachT, ReimanE, DoraiswamyP, SadowskyC, ColemanR, ClarkC, SchneiderJ, SabbaghM, AroraA, FlitterM (2012) Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: A prospective cohort study. Lancet Neurol11, 669–678.
22.
WongDF, RosenbergPB, ZhouY, KumarA, RaymontV, RavertHT, DannalsRF, NandiA, BrasicJR, YeW, HiltonJ, LyketsosC, KungHF, JoshiAD, SkovronskyDM, PontecorvoMJ (2010) In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (Florbetapir F 18). J Nucl Med51, 913–920.
23.
ClarkCM (2011) Use of Florbetapir-PET for imaging β-amyloid pathology. JAMA305, 275.
24.
AizensteinHJ, NebesRD, SaxtonJA, PriceJC, MathisCA, TsopelasND, ZiolkoSK, JamesJA, SnitzBE, HouckPR, BiW, CohenAD, LoprestiBJ, DeKoskyST, HalliganEM, KlunkWE (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol65, 1509–1517.
JackCR, KnopmanDS, JagustWJ, ShawLM, AisenPS, WeinerMW, PetersenRC, TrojanowskiJQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol9, 119–128.
27.
MinoshimaS, GiordaniB, BerentS, FreyKA, FosterNL, KuhlDE (1997) Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol42, 85–94.
28.
AbdullaS, SalavatiA, SabouryB, BasuS, TorigianDA, AlaviA (2014) Quantitative assessment of global lung inflammation following radiation therapy using FDG PET/CT: A pilot study. Eur J Nucl Med Mol Imaging41, 350–356.
29.
PeterJ, HoushmandS, WernerTJ, RubelloD, AlaviA (2016) Applications of global quantitative18F-FDG-PET analysis in temporal lobe epilepsy. Nucl Med Commun37, 223–30.
30.
PeterJ, HoushmandS, WernerTJ, RubelloD, AlaviA (2016) Novel assessment of global metabolism by 18F-FDG-PET for localizing affected lobe in temporal lobe epilepsy. Nucl Med Commun37, 882–887.
31.
BasuS, Hoilund-CarlsenPF, AlaviA (2012) Assessing global cardiovascular molecular calcification with 18F-fluoride PET/CT: Will this become a clinical reality and a challenge to CT calcification scoring? Eur J Nucl Med Mol Imaging39, 660–664.
32.
BeheshtiM, SabouryB, MehtaNN, TorigianDA, WernerT, MohlerE, WilenskyR, NewbergAB, BasuS, LangstegerW, AlaviA (2011) Detection and global quantification of cardiovascular molecular calcification by fluoro-18-fluoride positron emission tomography/computed tomography-A novel concept. Hell J Nucl Med14, 114–120.
33.
SabouryB, SalavatiA, BrothersA, BasuS, KweeTC, LamMGEH, HustinxR, LouisE, TorigianDA, AlaviA (2014) FDG PET/CT in Crohn’s disease: Correlation of quantitative FDG PET/CT parameters with clinical and endoscopic surrogate markers of disease activity. Eur J Nucl Med Mol Imaging41, 605–614.
34.
SabouryB, ParsonsMA, MoghbelM, RubelloD, BrothersA, TorigianDA, WernerTJ, HoushmandS, BasuS, LamMGEH, AlaviA (2016) Quantification of aging effects upon global knee inflammation by18F-FDG-PET. Nucl Med Commun37, 254–258.
35.
LangbaumJBS, ChenK, LeeW, ReschkeC, FleisherAS, AlexanderGE, FosterNL, MichaelW, KoeppeRA, JagustWJ, ReimanEM; Alzheimer’s Disease Neuroimaging Initiative (2010) Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Neuroimage45, 1107–1116.
36.
ClarkCM, SchneiderJA, BedellBJ, BeachTG, BilkerWB, MintunM a, PontecorvoMJ, HeftiF, CarpenterAP, FlitterML, KrautkramerMJ, KungHF, ColemanRE, DoraiswamyPM, FleisherAS, SabbaghMN, SadowskyCH, ReimanEP, ZehntnerSP, SkovronskyDM (2011) Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA305, 275–283.
37.
DukartJ, MuellerK, HorstmannA, VogtB, FrischS, BarthelH, BeckerG, MöllerHE, VillringerA, SabriO, SchroeterML (2010) Differential effects of global and cerebellar normalization on detection and differentiation of dementia in FDG-PET studies. Neuroimage49, 1490–1495.
38.
MorrisE, ChalkidouA, HammersA, PeacockJ, SummersJ, KeevilS (2016) Diagnostic accuracy of 18F amyloid PET tracers for the diagnosis of Alzheimer’s disease: A systematic review and meta-analysis. Eur J Nucl Med Mol Imaging43, 374–385.
39.
YangL, RievesD, GanleyC (2012) Brain amyloid imaging — FDA approval of Florbetapir F18 Injection. N Engl J Med367, 885–887.
40.
FantoniER, ChalkidouA, O’BrienJT, FarrarG, HammersA (2018) A systematic review and aggregated analysis on the impact of amyloid PET brain imaging on the diagnosis, diagnostic confidence, and management of patients being evaluated for Alzheimer’s disease. J Alzheimers Dis63, 783–796.
AschenbrennerAJ, GordonBA, BenzingerTLS, MorrisJC, HassenstabJJ (2018) Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology91, e859–e866.
43.
ForsbergA, EnglerH, AlmkvistO, BlomquistG, HagmanG, WallA, RingheimA, LångströmB, NordbergA (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging29, 1456–1465.
44.
JackCR, LoweVJ, SenjemML, WeigandSD, KempBJ, ShiungMM, KnopmanDS, BoeveBF, KlunkWE, MathisCA, PetersenRC (2008) 11C PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain131, 665–680.
45.
RabinoviciGD, JagustWJ (2009) Amyloid imaging in aging and dementia: Testing the amyloid hypothesis in vivo. Behav Neurol21, 117–128.
46.
JohnsonKA, SperlingRA, GidicsinCM, CarmasinJS, MayeJE, ColemanRE, ReimanEM, SabbaghMN, SadowskyCH, FleisherAS, Murali DoraiswamyP, CarpenterAP, ClarkCM, JoshiAD, LuM, GrundmanM, MintunMA, PontecorvoMJ, SkovronskyDM (2013) Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer’s disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement9, S72–S83.
SmailagicN, VacanteM, HydeC, MartinS, UkoumunneO, SachpekidisC (2015) 18F-FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst RevCD010632.
49.
NewbergAB, ArnoldSE, WinteringN, RovnerBW, AlaviA (2012) Initial clinical comparison of 18F-Florbetapir and 18F-FDG PET in patients with Alzheimer disease and controls. J Nucl Med53, 902–907.
50.
BennettDA, CochranEJ, SaperCB, LeverenzJB, GilleyDW, WilsonRS (1993) Pathological changes in frontal cortex from biopsy to autopsy in Alzheimer’s disease. Neurobiol Aging14, 589–596.
51.
ReedBR, WeinerMW, JagustWJ, MadisonCM, MarchantNL, DeCarliCS, ChuiHC (2011) Cerebrovascular disease, beta-amyloid, and cognition in aging. Neurobiol Aging33, 1006.e25–1006.e36.
52.
PikeKE, EllisKA, VillemagneVL, GoodN, ChételatG, AmesD, SzoekeC, LawsSM, VerdileG, MartinsRN, MastersCL, RoweCC (2011) Cognition and beta-amyloid in preclinical Alzheimer’s disease: Data from the AIBL study. Neuropsychologia49, 2384–2390.
53.
MosconiaL, BertiaV, GlodzikaL, PupibA, De SantiaS, De Leon MJ (2011) Pre-clinical detection of Alzheimer’s disease using FDG-PET, with or without amyloid imaging. Alzheimers Dement6, 843–854.
54.
EnglerH, ForsbergA, AlmkvistO, BlomquistG, LarssonE, SavitchevaI, WallA, RingheimA, LångströmB, NordbergA (2006) Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease. Brain129, 2856–2866.
55.
EdisonP, ArcherHA, HinzR, HammersA, PaveseN, TaiYF, HottonG, CutlerD, FoxN, KennedyA, RossorM, BrooksDJ (2007) Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study. Neurology68, 501–508.
56.
OssenkoppeleR, TolboomN, Foster-DingleyJC, AdriaanseSF, BoellaardR, YaqubM, WindhorstAD, BarkhofF, LammertsmaAA, ScheltensP, Van Der FlierWM, Van BerckelBNM (2012) Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. Eur J Nucl Med Mol Imaging39, 990–1000.
57.
DumurgierJ, HanseeuwBJ, HatlingFB, JudgeKA, SchultzAP, ChhatwalJP, BlackerD, SperlingRA, JohnsonKA, HymanBT, Gómez-IslaT (2017) Alzheimer’s disease biomarkers and future decline in cognitive normal older adults. J Alzheimers Dis60, 1451–1459.
58.
MoghbelMC, SabouryB, BasuS, MetzlerSD, TorigianDA, LångströmB, AlaviA (2012) Amyloid-β imaging with PET in Alzheimer’s disease: Is it feasible with current radiotracers and technologies? Eur J Nucl Med Mol Imaging39, 202–208.
59.
NestorPJ, FryerTD, SmielewskiP, HodgesJR (2003) Limbic hypometabolism in Alzheimer’s disease and mild cognitive impairment. Ann Neurol54, 343–351.
60.
De Santi S, De Leon MJ, RusinekH, ConvitA, TarshishCY, RocheA, TsuiWH, KandilE, BoppanaM, DaisleyK, WangGJ, SchlyerD, FowlerJ (2001) Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging22, 529–539.
61.
AltmannA, NgB, LandauSM, JagustWJ, GreiciusMD (2015) Regional brain hypometabolism is unrelated to regional amyloid plaque burden. Brain138, 3734–3746.
62.
MannDMA, MarcyniukB, YatesPO, NearyD, SnowdenJS (1988) The progression of the pathological changes of Alzheimer’s disease in frontal and temporal neocortex examined both at biopsy and at autopsy. Neuropathol Appl Neurobiol14, 177–195.
63.
BlessedG, TomlinsonBE, RothM (1968) The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry114, 797–811.
64.
LandauSM, MintunMA, JoshiAD, KoeppeRA, PetersenRC, AisenPS, WeinerMW, JagustWJ (2012) Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol72, 578–586.
65.
ParoniG, BiscegliaP, SeripaD (2019) Understanding the amyloid hypothesis in Alzheimer’s disease. J Alzheimers Dis68, 493–510.
66.
BrendelM, SchnabelJ, SchöneckerS, WagnerL, BrendelE, Meyer-WilmesJ, UnterrainerM, SchildanA, PattM, PrixC, AcklN, CatakC, PogarellO, LevinJ, DanekA, BuergerK, BartensteinP, BarthelH, SabriO, RomingerA (2017) Additive value of amyloid-PET in routine cases of clinical dementia work-up after FDG-PET. Eur J Nucl Med Mol Imaging44, 2239–2248.
